Fimepinostat - Curis

Drug Profile

Fimepinostat - Curis

Alternative Names: CUDC-907

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curis
  • Developer Curis; Dana-Farber Cancer Institute; National Cancer Institute (USA)
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action 1-phosphatidylinositol 4-kinase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Thyroid cancer
  • Phase I CNS cancer; Lymphoma; Solid tumours
  • No development reported Multiple myeloma

Most Recent Events

  • 02 Jan 2018 CUDC 907 is still in phase I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 09 Dec 2017 Safety and efficacy data from a phase II trial in Diffuse large B-cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top